The Challenge: Aggressive Disease, Multiple High-Risk Factors Converging

Dedifferentiated endometrial carcinoma (DDEC) is a rare but highly aggressive histologic subtype of endometrial cancer, accounting for approximately 2% of all cases and ~10% of high-grade tumors. It is characterized by early systemic dissemination, rapid clinical progression, and poor prognosis — approximately 40% of patients succumb within 0.5–20 months of diagnosis. The majority of DDEC cases exhibit mismatch repair deficiency (dMMR; 48–71%), which carries important therapeutic implications for immunotherapy responsiveness.

This case involves a 51-year-old woman whose postoperative course was immediately complicated by widespread multi-organ metastases (brain, lungs, liver, bones, peritoneum, retroperitoneal lymph nodes, vaginal stump) combined with multiple brain metastases, refractory cerebral edema, tentorial subfalcine herniation, and recurrent seizures with aphasia. Her Graded Prognostic Assessment (GPA) score was 0 (≥5 brain lesions with extracranial disease), predicting median survival of only ~3 months.

Patient Profile at Presentation

  • Age/Sex: 51-year-old female
  • Primary Diagnosis: Dedifferentiated endometrial carcinoma, Stage IIIB (surgical); IVB by PET-CT (occult M1 suspected)
  • Molecular Profile: dMMR (MLH1−, PMS2−), MSI-H, TMB-H (10.10 mut/Mb)
  • Surgery: Laparoscopic extrafascial hysterectomy + BSO + pelvic & para-aortic lymphadenectomy + omentectomy (April 2025)
  • Post-op PET-CT: Brain, bilateral lungs, liver, diffuse bone, vaginal stump, peritoneum, retroperitoneal LN mets
  • Baseline CA125: 34 U/ml
  • Neurological Complications: Multiple brain mets + cerebral edema + tentorial herniation + recurrent seizures + aphasia

Phase 1: First-Line Chemo-Immunotherapy + Whole-Brain Radiotherapy — Rapid Partial Response

Before her first chemotherapy infusion, the patient developed headache, dizziness, and communication difficulties. During paclitaxel infusion, she experienced abrupt hypertension with sinus arrhythmia and bradycardia — correctly recognized by the team as a Cushing response from elevated intracranial pressure (rather than a paclitaxel hypersensitivity reaction, which typically presents with hypotension and bronchospasm). Infusion was immediately stopped.

Critical Decision Point: The correct identification of hypertension + bradycraxia as an ICP elevation sign (Cushing triad) — rather than paclitaxel allergy — led to immediate head CT, detection of tentorial subfalcine herniation, and life-saving intervention within hours.

Head CT confirmed multiple brain metastases with severe cerebral edema and incipient tentorial herniation. Urgent management included mannitol and methylprednisolone for ICP reduction. Once stabilized, the Radiation Oncology MDT recommended urgent whole-brain radiotherapy (WBRT).

Treatment Protocol: May – September 2025

  • Regimen: Paclitaxel + Cisplatin + Pembrolizumab (6 cycles), concurrent with WBRT
  • Rationale for cisplatin over carboplatin: Reduced myelosuppression risk when combined with concurrent cranial irradiation
  • WBRT: Completed during Cycle 1; follow-up MRI at 1 month showed reduced brain mets and improved edema
  • Toxicities: Grade 2 myelosuppression, anorexia — manageable with supportive care

Response Assessment (September 2025): Partial Response

ParameterPre-treatmentPost-C3Post-C6
CA125 (U/ml)34.630.914.3
Brain MRIMultiple mets + severe edema—Reduced mets size, edema improved
Systemic CTWidespread mets—PR — peritoneal thickening, lung nodules stable

Gynecologic Oncology MDT assessment: Partial Response (PR). Given the MSI-H/dMMR profile with demonstrated immunotherapy benefit, the patient transitioned to pembrolizumab maintenance immunotherapy.

Phase 2: Intracranial Progression — Transitioning to ADC + Immunotherapy

In October 2025, while on maintenance immunotherapy, the patient suffered an unprovoked seizure (right upper arm twitching lasting 3–4 minutes, with transient inability to speak). Follow-up MRI revealed:

Levetiracetam was initiated for seizure prophylaxis. Despite this, she experienced intermittent episodes of speech apraxia, slowed responses, tinnitus, and limb paresthesias with progressive weight loss.

The MDT Decision: Sacituzumab Govitecan + Pembrolizumab

The Neuro-Oncology and Gynecologic Oncology MDTs convened for joint decision-making. Key considerations:

  1. Re-irradiation contraindicated: Repeat WBRT would carry unacceptable risks of brain atrophy and cognitive decline
  2. Chemotherapy limited by blood-brain barrier: Traditional cytotoxics poorly penetrate the CNS
  3. ADC rationale: Sacituzumab govitecan (a Trop-2-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload) has shown potential activity against brain metastases in clinical observations — possibly due to BBB disruption by tumor infiltration and the relatively small molecular weight of its payload
  4. Continuing immunotherapy justified: Tumor remains dMMR/MSI-H; discontinuing pembrolizumab would forfeit established benefit

Decision: Initiate sacituzumab govitecan + pembrolizumab, reassess after 4 cycles.

Phase 3: Individualized Toxicity Management — The Art of Dose Optimization

Cycles 1–2: Standard-Dose Toxicity Crisis

Sacituzumab govitecan was started at the standard dose of 5 mg/kg. After just two cycles:

The patient could not proceed to Cycle 3 at the current dose. MRI showed mixed response: right cerebellar and left parietal-occipital lesions slightly reduced, but frontal lesions and surrounding edema had increased.

MDT Insight: Clinical trials report sacituzumab govitecan's mean time-to-response as ~1.5 months (3–4 cycles). The team elected to continue therapy rather than abandon it — but required dose modification to ensure sustainable delivery.

Dose Reduction: 5 mg/kg → 4 mg/kg

Cycle 3 proceeded at 4 mg/kg. Anemia improved significantly, enabling regular treatment scheduling. However, at home between cycles, the patient experienced recurrent seizures with limb numbness, pain, and weakness. Neurological exam showed mild left-sided weakness.

Single-Dose Bevacizumab: The Turning Point for Cerebral Edema

The Neuro-Oncology MDT reviewed serial MRIs and concluded overall response was stable disease (SD). The worsening symptoms were attributed to diffuse cerebral edema — likely treatment-related vascular permeability changes (vascularitis-like phenomenon) rather than pure tumor progression. A key recommendation emerged:

Add single-dose bevacizumab 200 mg IV — not as antitumor therapy, but as an anti-vascular-leakage maneuver to reduce cerebral edema and control seizures.

Important safety consideration: Bevacizumab carries bleeding risk, and this patient had a left frontal lesion suggestive of cavernous malformation hemorrhage. The benefit-risk analysis favored administration after thorough discussion with the patient and family.

Result: After the single bevacizumab dose, seizures ceased completely. The patient completed Cycles 4–8 with stable disease, manageable anemia, and no further seizure events.

Long-Term Outcome: Sustained Stability Beyond Expectations

After Cycle 8, the patient experienced another seizure episode following sun exposure. MRI showed:

Neuro-Oncology MDT interpreted the right frontal lesion as having slightly higher metabolism while the left frontal lesion showed low metabolism consistent with treatment necrosis. Overall assessment remained SD. A second single dose of bevacizumab (200 mg) was given alongside increased levetiracetam dosing.

Cycles 9–12 (March – May 2026)

The patient completed 12 total cycles of sacituzumab govitecan (4 mg/kg) + pembrolizumab. Main toxicities were controllable myelosuppression and transaminase elevations. No further definite seizure episodes occurred.

Clinical Achievement

  • Time from brain herniation event to last follow-up: ~13 months of disease stability
  • vs. GPA-predicted median survival: ~3 months (>4× extension)
  • Extracranial disease: Controlled (no FDG-avid lesions on PET-CT)
  • Quality of life: Ambulatory, communicative, seizure-free after bevacizumab intervention
  • Ongoing treatment: Continues on sacituzumab govitecan + pembrolizumab per MDT plan

Key Clinical Insights

  1. dMMR-directed first-line chemo-immunotherapy is evidence-based: NRG-GY018 (dMMR PFS HR 0.30) and RUBY trials (HR 0.28) establish chemotherapy + immunotherapy as standard of care for recurrent/metastatic dMMR endometrial cancer. This patient's rapid PR validated the approach.
  2. ADC drugs represent a rational post-progression option for brain mets: When immunotherapy alone fails to control intracranial disease, Trop-2-targeted ADC agents may achieve CNS penetration through disrupted blood-brain barriers. This case provides real-world support for this mechanism-based strategy.
  3. Individualized dose reduction preserves treatment continuity: Reducing sacituzumab govitecan from 5→4 mg/kg transformed an intolerable regimen into a sustainable one — without apparent loss of efficacy over 12 cycles. This exemplifies chronic-disease-model thinking in advanced cancer management.
  4. Low-dose bevacizumab is a powerful edema-control tool: A single 200 mg dose (anti-permeability, not antitumor dosage) eliminated seizures and improved neurological status — reducing reliance on long-term corticosteroids that could potentially antagonize immunotherapy efficacy.
  5. Discriminating true progression from pseudo-progression is critical: Serial MRI and PET-CT revealed that some enlarging lesions represented treatment necrosis rather than tumor growth. Avoiding premature treatment change preserved an effective regimen.
  6. MDT collaboration is non-negotiable: Every critical decision — from herniation recognition through dose adjustment to edema management — was made through structured MDT discussion across gynecologic oncology, neuro-oncology, radiation oncology, radiology, and clinical pharmacy.

Expert Commentary

Prof. Wu Ming

Prof. Wu Ming Beijing Union Medical College Hospital (PUMCH), Gynecologic Oncology

1. Standard Decision-Making for Brain Metastasis Emergency and Initial Systemic Treatment

This patient presented with multiple brain metastases complicated by severe cerebral edema and tentorial subfalcine herniation — a life-threatening scenario. Before initiating systemic therapy, the team rapidly recognized the intracranial hypertensive crisis and delivered urgent mannitol and methylprednisolone, buying critical time for definitive intervention. Once stabilized, radiation oncology promptly implemented whole-brain radiotherapy while the gynecologic oncology team simultaneously launched paclitaxel-cisplatin-pembrolizumab based on the dMMR/MSI-H molecular classification. This synchronous approach — local cranial control plus systemic chemo-immunotherapy — followed current guidelines and demonstrated sound clinical judgment under pressure.

2. Precision Combination Strategy Upon Intracranial Progression

After achieving extracranial PR, the patient's intracranial disease progressed with new frontal lesions and worsening edema. Rather than abandoning immunotherapy, the team retained pembrolizumab (justified by persistent dMMR biology) and introduced sacituzumab govitecan. This decision leveraged two principles: (1) continued ICI benefit in MSI-H disease, and (2) the theoretical CNS penetration of ADC payloads when BBB integrity is compromised by tumor infiltration. Subsequent imaging confirmed response — some lesions shrank, others showed metabolic suppression consistent with necrosis — validating the scientific reasoning behind this combination.

3. Longevity-Focused Toxicity Management and Dose Adjustment

The emergence of grade 3 thrombocytopenia and refractory anemia after two cycles at 5 mg/kg created a crossroads: abandon an effective but toxic regimen, or modify it intelligently. The team chose the latter — reducing to 4 mg/kg based on pharmacokinetic understanding of the drug's toxicity-efficacy window. Anemia resolved, treatment rhythm normalized, and disease stability persisted across subsequent cycles. This represents the essence of managing advanced cancer as a chronic condition: prioritizing sustainable drug delivery over maximum-intensity dosing that leads to treatment interruption.

4. Discriminatory Efficacy Assessment and Seizure Etiology Differentiation

Throughout treatment, the patient's neurological symptoms fluctuated — seizures, limb weakness, speech difficulties — while imaging showed variable changes in lesion size and edema. A superficial interpretation might have triggered premature treatment change. Instead, the team employed serial contrast-enhanced MRI and PET-CT to differentiate tumor progression from treatment-related necrosis and identified vascular permeability-mediated edema as a reversible contributor. This nuanced reading allowed continuation of an effective regimen while adding targeted edema control (bevacizumab), resulting in seizure cessation and functional improvement. The principle is clear: in brain metastasis management, not every radiographic or clinical worsening represents true disease progression.

5. Central Role of Multidisciplinary Collaboration

Every pivotal decision in this case — from WBRT timing selection to ADC-combination formulation, from dose-adjustment strategy to anti-edema intervention — originated from structured MDT deliberation. Neuro-oncology provided expert intracranial image interpretation and seizure etiology discrimination; radiation oncology assessed re-irradiation risks; gynecologic oncology managed systemic therapy optimization; pharmacy guided toxicity mitigation. For a case defined by multiple brain metastases, fluctuating neurological status, and competing risk-benefit calculations, MDT was not merely beneficial — it was the institutional infrastructure that made long-term survival possible.

Prof. Sun Min

Prof. Sun Min University of Pittsburgh Medical Center (UPMC), USA

I. Epidemiological Context & Prognostic Positioning

Dedifferentiated endometrial carcinoma (DDEC) is rare yet disproportionately lethal — comprising ~2% of endometrial cancers but ~10% of high-grade cases, with up to 71% exhibiting dMMR status. Molecular classification outperforms histology for prognostication: dMMR DDEC has meaningfully better outcomes than p53-aberrant DDEC. Notably, DDEC shows a ~4-fold overrepresentation in endometrial cancer brain metastasis series (8% vs. baseline 0.7%), and non-endometrioid histologies harbor significantly more brain lesions per case (6.21 vs. 2.44, P=0.029).

Clinical inference: In DDEC patients, intracranial involvement should be regarded as a high-risk endpoint warranting proactive surveillance. Any new neurological symptom should trigger low-threshold brain MRI.

This patient's GPA score was 0 (≥5 brain mets + extracranial disease), predicting median survival of only ~3 months. Achieving ~13 months of disease stability through sequential therapy represents a >4-fold extension beyond stratified baseline expectations — driven not by any single drug's miraculous effect, but by the team's accurate recognition and sustained exploitation of dMMR biology.

II. Diagnostic and Therapeutic Highlights

1. dMMR-guided first-line chemo-immunotherapy: Directionally correct and fully evidenced. NRG-GY018 reported dMMR-subgroup PFS HR of 0.30; RUBY reported HR 0.28. First-line CA125 dropped from 34.6 to 14.3 U/ml; intra- and extracranial lesions achieved PR — entirely consistent with trial benchmarks.

2. Precise crisis interpretation during infusion: The "hypertension + sinus bradycardia" during paclitaxel infusion was correctly identified as a Cushing response from elevated ICP — not the hypotension/bronchospasm pattern of paclitaxel hypersensitivity. Immediate cessation and CT scanning detected tentorial herniation, averting fatal delay.

3. Decisive acute herniation management: Mannitol + methylprednisolone for ICP reduction followed by urgent WBRT — standard-of-care for multiple brain mets with herniation.

4. Low-dose bevacizumab for refractory cerebral edema — the single highest-yield symptomatic intervention: 200 mg represents an anti-vascular-leakage (not antitumor) dose. Low-dose efficacy is non-inferior to standard doses for edema indication, while simultaneously reducing long-term corticosteroid dependence — avoiding their potential antagonistic effect on immunotherapy efficacy. Seizures ceased permanently after a single administration.

5. Rigorous MDT documentation throughout the entire treatment trajectory: Every key node featured recorded multidisciplinary discussion — creating a reproducible clinical pathway for future similar cases.

References

  1. Mourtzoukou D, et al. Undifferentiated-Dedifferentiated Endometrial Carcinoma. APMIS. 2023;131(6):229-236.
  2. Huang CY, et al. Distinct Genomic Subgroups in DDEC. BMC Cancer. 2025;25(1):1540.
  3. Dagher C, et al. Molecular Subtypes and Genomic Landscape of DDEC. Int J Gynecol Cancer. 2025;35(5):101815.
  4. Hammer PM, et al. Molecular Classification Outperforms Histology in High-Grade EC. AJSP. 2024;48(8):953-964.
  5. Nasioudis D, et al. Brain Metastases From Gynecologic Malignancies. Am J Clin Oncol. 2020;43(6):418-421.
  6. Gien LT, et al. Brain Metastases From Endometrial Carcinoma. Gynecol Oncol. 2004;93(2):524-528.
  7. Uccella S, et al. Primary Brain Metastases of Endometrial Cancer: 18 Cases. Gynecol Oncol. 2016;142(1):70-75.
  8. Chura JC, et al. Multimodal Therapy in CNS Metastasis From Uterine Cancer. Gynecol Oncol. 2007;107(1):79-85.
  9. Sambataro D, et al. Brain Metastasis in Endometrial Cancer: Systematic Review. Cancers. 2025;17(3):402.
  10. Bhambhvani HP, et al. Brain Metastases From Endometrial Cancer: Review. World Neurosurg. 2021;147:e32-e39.
  11. Hayashi N, et al. GPA for Brain Metastases From Uterine Cancer. BMC Cancer. 2017;17(1):397.

Seek Expert Second Opinion for Complex Cancer Cases

If you or your loved one faces a complex oncology diagnosis like dedifferentiated endometrial carcinoma with brain metastases, Beijing Arion Cancer Hospital's multidisciplinary tumor board can provide a comprehensive treatment evaluation.

Request Consultation →